A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

NCT02010970 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Pharmacologic Action

Interventions

DRUG: Group 1 AZD3293
DRUG: Group 2 AZD3293
DRUG: Group 3 AZD3293
DRUG: Group 1 Itraconazole
DRUG: Group 2 Diltiazem
DRUG: Group 3 Midazolam

Sponsor

AstraZeneca